Nelsen Biomedical
Nelsen Biomedical is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Nelsen Biomedical.
Nelsen Biomedical is a company.
Key people at Nelsen Biomedical.
Nelsen Biomedical is a life sciences strategy consulting firm specializing in defining market opportunities, developing, and implementing strategic plans for biotech and life sciences companies.[1][3] Founded by Barbara Nelsen, it helps build businesses in the industry by leveraging her 20+ years of experience in R&D, business, and strategic development, with offices in Minneapolis and Boston to connect Midwest clients to East Coast and Silicon Valley resources.[3][4][5] The firm generates around $14 million in revenue and operates in biotechnology and business services, focusing on high-impact areas like cell therapy and gene editing.[2][4]
Nelsen Biomedical was founded by Barbara Nelsen, a life sciences strategist with over two decades in R&D, business development, and strategy.[3][5] The idea emerged from Minnesota's nascent biotech scene, prompting expansion from a Minneapolis base to a Boston office in 2013 to bridge regional gaps and access major industry hubs.[4] Key pivotal moments include Nelsen's involvement in innovative projects, such as highlighting breakthroughs in CAR-T cell therapy (e.g., Novartis' Kymriah with 83% remission rates) and supporting Midwest firms like Wilson Wolf on cell therapy cost-of-goods-sold challenges.[4]
Nelsen Biomedical rides the wave of regenerative medicine and advanced biotech trends, such as CAR-T therapies achieving long-term cancer remissions (e.g., five-year cancer-free outcomes akin to the pacemaker's impact) and scalable gene editing.[4] Timing is ideal amid biotech's shift toward one-and-done treatments and cost reductions in cell therapy, fueled by market forces like FDA approvals and university spinouts (e.g., B-MoGen from University of Minnesota).[4][6] It influences the ecosystem by fostering Midwest growth, advising on immune programming at scale for infectious diseases, and building connections that accelerate regional innovation.[4][6]
Nelsen Biomedical is poised to expand its influence as biotech matures, particularly in cell/gene therapies and tools from firms like B-MoGen and Bio-Techne, amid rising demand for strategic guidance in a fragmented industry.[4] Trends like unprecedented immune programming and COGS breakthroughs in cell therapy will shape its trajectory, potentially amplifying its role in bridging heartland biotech to global hubs.[4][6] Its network-driven model positions it to drive more university-backed ventures, evolving from consultant to key ecosystem architect in life sciences' next phase of transformative solutions.
Key people at Nelsen Biomedical.
